Surmodics remains in the midst of being acquired by GTCR, with completion pending regulatory approval. The $43.00-per-share all-cash deal offers potential liquidity for shareholders, but litigation by ...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare ...